PAVmed Inc. (PAVM) Earnings Call Transcripts
PAVmed Inc.'s Latest Earnings Call - Q1 FY2026
In the first quarter of 2026, PAVmed Inc. reported a GAAP net loss of $1.1 million, a significant decline from a profit of $18.6 million in the prior year, primarily due to changes in the fair value of Lucid shares. The company has successfully completed its restructuring, which management believes positions PAVmed for growth as it relaunches its medical device portfolio and evaluates new opportunities. Management expressed confidence in upcoming milestones for both Lucid Diagnostics and Veris, particularly regarding Medicare coverage and the commercial rollout of the Veris platform.
Reported metrics
| Metric | Value |
|---|---|
| GAAP Net Loss | $1.1 million (miss) |
| GAAP Loss Per Share | $4.42 (miss) |
| Cash Position | $6.5 million (neutral) |
| Non-GAAP Operating Expenses | $5.9 million (negative) |
| Lucid Shares Mark-to-Market | $36 million (positive) |
| Shares Outstanding | 7.3 million (neutral) |
Guidance from management
Management did not provide specific numerical guidance for future quarters but expressed confidence in the upcoming milestones for both Lucid and Veris, indicating a focus on expanding commercial opportunities as capital allows.
What analysts pressed on
Analysts raised questions regarding the timeline for Medicare coverage for Lucid and the ramp-up of patient enrollment in the Veris platform. There were also concerns about the sustainability of operating expenses given the recent increases and the impact on future profitability.
Main topics on the call
- Restructuring Completion — PAVmed has completed a two-year restructuring process, resulting in a 'clean' capital structure consisting solely of common stock and term debt. This restructuring is expected to facilitate growth and new opportunities f...
- Medical Device Portfolio Relaunch — The company is relaunching its medical device portfolio under Joe Virgilio, focusing on advancing technologies like PortIO and endoscopic imaging. Management believes this dedicated approach will enhance capital raising ...
- Lucid Diagnostics Progress — Lucid is nearing key milestones, including potential Medicare coverage, which management views as transformative. They remain optimistic despite frustrations over delays, indicating that 'our confidence has not wavered.'
- Veris Platform Development — The Veris platform is progressing well in its commercial phase with Ohio State University, with plans to expand to additional departments. Management noted that the clinical rollout is 'on target' to meet enrollment goal...
Read the full PAVmed Inc. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About PAVmed Inc.
PAVmed Inc. (PAVM) is a publicly listed company in the Health Care Equipment and Supplies industry, within the Health Care sector. It trades on NasdaqCM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 37 calls on record spanning April 9, 2020 to June 24, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 37 PAVmed Inc. earnings call transcripts on record, spanning April 9, 2020 to June 24, 2026. Based on this history, PAVmed Inc. reports quarterly. The most recent call on file is dated June 24, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- PAVM
- Exchange
- NasdaqCM
- Country
- US
- Sector
- Health Care
- Calls on record
- 37
- First call
- April 9, 2020
- Most recent
- June 24, 2026
- Reporting cadence
- quarterly